16.2 Bone & Joint Diseases: Non-Traumatic Arthropathies & Metabolic Bone Disorders

Clinical Approach to Joint & Bone Disorders

Non-traumatic joint and bone diseases represent a major clinical workload in primary care and inpatient medicine. For the CAMC Registration Examination, candidates must be adept at differentiating inflammatory from non-inflammatory (degenerative) joint disorders, interpreting diagnostic synovial fluid arthrocentesis, recognizing orthopedic emergencies such as acute septic arthritis, applying DMARD pharmacotherapy guidelines, and distinguishing metabolic bone diseases using biochemical markers and radiographic findings.

---

Rheumatoid Arthritis (RA)

Rheumatoid Arthritis is a chronic, systemic, inflammatory autoimmune disorder characterized by persistent symmetrical polyarthritis primarily targeting the synovial membranes of diarthrodial joints. Uncontrolled synovitis leads to chronic cartilage destruction, marginal bone erosions, and progressive joint deformity.

Pathophysiology

• Genetic Susceptibility: Strong link to HLA-DRB1 alleles containing the shared epitope (SE), such as HLA-DR4 and DR1. Environmental triggers (notably cigarette smoking and periodontal disease with Porphyromonas gingivalis) stimulate mucosal peptidylarginine deiminase (PAD) enzymes, causing post-translational citrullination of self-proteins (vimentin, fibrinogen, collagen).
• Synovial Pannus: Autoreactive CD4+ Th1 and Th17 cells activate B cells to produce Anti-Cyclic Citrullinated Peptide (Anti-CCP) antibodies and Rheumatoid Factor (RF). Infiltrating macrophages secrete pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6). Synovial fibroblasts and osteoclasts proliferate, forming an invasive fibrovascular tissue mass—the pannus—that invades and degrades articular cartilage and underlying periarticular subchondral bone via matrix metalloproteinases (MMPs) and RANK-ligand signaling.

Clinical Manifestations

• Articular Presentation: Insidious onset of symmetrical, additive polyarthritis predominantly involving peripheral small joints: metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, wrists, and metatarsophalangeal (MTP) joints. Notably, RA characteristically spares the distal interphalangeal (DIP) joints and the thoracolumbar spine.
• Morning Stiffness: Prolonged, lasting > 1 hour, characteristically improving with joint movement, warm showers, and physical activity (in contrast to degenerative joint disease).
• Late Deformities:
  • Swan-Neck Deformity: Hyperextension of the PIP joint with compensatory flexion of the DIP joint.
  • Boutonnière Deformity: Flexion of the PIP joint with hyperextension of the DIP joint (rupture of central extensor tendon slip).
  • Ulnar Deviation: Subluxation and ulnar drift of the fingers at the MCP joints.
  • Z-Deformity of the Thumb: Severe hyperextension of the interphalangeal joint with flexion of the MCP joint.
  • Baker (Popliteal) Cyst: Posterior extension of knee joint synovitis into the gastrocnemio-semimembranosus bursa; rupture mimics acute deep vein thrombosis (pseudothrombophlebitis).
• Extra-Articular Manifestations:
  • Rheumatoid Nodules: Firm, painless, non-tender subcutaneous granulomas over extensor pressure surfaces (olecranon, Achilles tendon).
  • Ocular: Episcleritis, scleritis (painful, violaceous, visual threat), and secondary Sjögren syndrome.
  • Pulmonary: Exudative pleural effusions (characteristically low glucose < 1.6 mmol/L [< 30 mg/dL]), interstitial lung disease (fibrosing alveolitis), and pulmonary rheumatoid nodules (Caplan syndrome when combined with coal workers' pneumoconiosis).
  • Hematologic: Anemia of chronic disease; Felty Syndrome (triad of severe seropositive RA, splenomegaly, and severe neutropenia [ANC < 1,000/µL], conferring extreme risk of life-threatening pyogenic infections).

Critical Safety Alert: Atlantoaxial Subluxation & Elective Surgery

Rheumatoid pannus can erode the odontoid process (dens) and transverse odontoid ligament of C1-C2, leading to atlantoaxial cervical spine subluxation. Minor neck trauma or cervical hyperextension during endotracheal intubation can cause posterior displacement of the dens, resulting in acute spinal cord compression, spastic quadriparesis, respiratory arrest, or sudden death.

• Mandatory Preoperative Rule: All patients with long-standing or moderate-to-severe RA scheduled for elective surgery requiring general anesthesia must undergo preoperative cervical spine radiographs in flexion and extension to evaluate the anterior atlanto-dens interval (ADI). An ADI > 3 mm in adults indicates cervical instability requiring fiberoptic intubation without neck manipulation.

Investigations & Serology

• Anti-Cyclic Citrullinated Peptide (Anti-CCP / ACPA): Sensitivity ~75%, specificity ~96% to 98%. The single best diagnostic marker; detects early disease and strongly predicts an aggressive, rapidly erosive clinical course.
• Rheumatoid Factor (RF): Autoantibody (typically IgM) directed against the Fc fragment of human IgG. Sensitivity ~70-80%, but poor specificity (positive in Sjögren syndrome, SLE, chronic hepatitis C, subacute bacterial endocarditis, and healthy elderly).
• Plain Radiographs: Early changes show periarticular soft tissue swelling and periarticular osteopenia (juxta-articular demineralization); progressing to symmetrical joint space loss and pathognomonic marginal bone erosions at bare areas of joint margins.

Pharmacotherapy of Rheumatoid Arthritis

1. Conventional Synthetic DMARDs (csDMARDs) — Methotrexate Anchor:
   • First-Line Drug of Choice: Oral or subcutaneous Methotrexate (MTX) (10 to 25 mg once weekly) initiated immediately upon diagnosis ("treat-to-target" strategy to prevent irreversible joint destruction).
   • Mandatory Co-Prescription: Folic acid (5 mg weekly taken 24 to 48 hours after methotrexate, or 1 mg daily except on MTX day) to prevent oral stomatitis, nausea, transaminitis, and bone marrow toxicity.
   • Toxicity Monitoring: Full blood count (FBC), liver function tests (LFTs), and serum creatinine at baseline, every 2 to 4 weeks during initiation/titration, and every 8 to 12 weeks during maintenance.
   • Contraindications: Pregnancy (stop before maternal conception according to specialist/local guidance; paternal low-dose exposure <= 25 mg/week is compatible with pregnancy); severe liver impairment (cirrhosis); severe renal impairment (eGFR < 30 mL/min).
   • Alternative/Adjunctive csDMARDs: Sulfasalazine, Leflunomide, Hydroxychloroquine (frequently combined as "triple therapy": MTX + Sulfasalazine + HCQ).
2. Biologic DMARDs (bDMARDs) & Targeted Synthetic DMARDs (tsDMARDs):
   • Indicated when disease activity remains moderate or high despite optimized csDMARD therapy.
   • TNF-alpha Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab.
   • Non-TNF Biologics: Tocilizumab (IL-6 receptor antagonist), Abatacept (CTLA-4-Ig T-cell costimulation inhibitor), Rituximab (anti-CD20).
   • JAK Inhibitors (tsDMARDs): Tofacitinib, Baricitinib, Upadacitinib (oral targeted small molecules).
3. CRITICAL MANDATORY INFECTION SCREENING PRIOR TO BIOLOGICS:
   • TNF-alpha is essential for macrophage activation and the maintenance of granulomas that sequester Mycobacterium tuberculosis.
   • Prior to initiating ANY biologic DMARD or JAK inhibitor, mandatory screening for latent tuberculosis (LTBI) using an Interferon-Gamma Release Assay (IGRA, e.g., QuantiFERON-TB Gold) or Mantoux Tuberculin Skin Test (TST) PLUS a baseline chest radiograph must be performed. If LTBI is identified, a full course of preventive anti-tuberculosis therapy (e.g., isoniazid for 9 months, or rifampin/isoniazid for 3 months) must be initiated at least 1 month prior to starting the biologic.
   • Viral Hepatitis Screening: Mandatory testing for Hepatitis B (HBsAg and anti-HBc total) and Hepatitis C (anti-HCV) to prevent fatal viral reactivation.

---

Osteoarthritis (OA)

Osteoarthritis is the most prevalent joint disease worldwide, characterized as a progressive, degenerative non-inflammatory biomechanical disorder involving the entire diarthrodial joint: progressive loss and fibrillation of articular hyaline cartilage, subchondral bone remodeling, marginal osteophyte formation, and low-grade secondary synovial inflammation.

Pathophysiological & Clinical Comparison: RA vs OA

Radiographic Hallmarks of Osteoarthritis (The "LOSS" Tetrad)

Standard weight-bearing plain radiographs demonstrate four classic cardinal features:

• L — Loss of joint space: Asymmetrical, non-uniform joint space narrowing (focal to the zone of maximal biomechanical loading, e.g., medial compartment of the knee).
• O — Osteophytes: Marginal bone spurs developing at joint margins in response to altered mechanical loading.
• S — Subchondral sclerosis: Thickening and increased bone density (eburnation) of subchondral bone beneath thinned cartilage.
• S — Subchondral cysts: Geodes or cystic lucencies formed by microfractures or synovial fluid extrusion under high intra-articular pressure.

Management of Osteoarthritis

1. Core Non-Pharmacological Measures (First-Line for ALL Patients): Structured low-impact aerobic exercise, quadriceps muscle strengthening, weight reduction (each 1 kg weight loss reduces knee joint load by 4 kg), biomechanical footwear, walking aids, and patient education.
2. Pharmacotherapy:
   • Topical NSAIDs (e.g., topical diclofenac gel): Recommended first-line pharmacological agent for knee and hand OA, providing equivalent pain relief to oral NSAIDs with minimal systemic absorption and negligible GI/cardiovascular toxicity.
   • Oral NSAIDs / COX-2 Inhibitors: For patients refractory to topical therapy. Must always be co-prescribed with an oral Proton Pump Inhibitor (PPI) for gastroprotection in patients at risk of peptic ulcer disease. Use lowest effective dose for shortest duration; exercise extreme caution in chronic kidney disease, hypertension, and heart failure.
   • Intra-Articular Corticosteroids: Provide short-term (2 to 4 weeks) pain relief for acute inflammatory flare-ups with joint effusion.
3. Surgical Joint Arthroplasty: Total knee or hip replacement is indicated for severe refractory pain, night pain, and substantial functional impairment that fail conservative multimodal management.

---

Crystal-Induced Arthropathies

Crystal arthropathies are acute inflammatory joint disorders caused by the deposition of microcrystals within synovial fluid and periarticular tissues, inciting intense phagocytosis and neutrophil activation.

Acute Gout vs Pseudogout (CPPD)

+---------------------------------------------------------------------------------------------------+
|                         CRYSTAL ARTHROPATHIES: COMPARATIVE CLINICAL MATRIX                         |
+---------------------------------------------------------------------------------------------------+
| FEATURE                 | ACUTE GOUT                           | PSEUDOGOUT (CPPD)                |
+-------------------------+--------------------------------------+----------------------------------+
| Precipitating Crystal   | Monosodium Urate (MSU)               | Calcium Pyrophosphate (CPPD)     |
| Crystal Shape           | Needle-shaped, fine, pointed ends    | Rhomboid-shaped, rectangular     |
| Polarized Birefringence | STRONGLY NEGATIVE Birefringence      | WEAKLY POSITIVE Birefringence    |
| Compensator Color       | Bright YELLOW when parallel to axis; | BLUE when parallel to axis;      |
|                         | BLUE when perpendicular              | YELLOW when perpendicular        |
| Classic Joint Site      | 1st Metatarsophalangeal (MTP) joint  | Knee (over 50% of cases),        |
|                         | ("Podagra" in > 50% of first attacks)| wrist, shoulder, symphysis pubis |
| Radiographic Signs      | "Punched-out" periarticular erosions| Chondrocalcinosis (calcification |
|                         | with overhanging sclerotic margins   | of hyaline or fibrocartilage)    |
| Pathophysiological Basis| Hyperuricemia (urate > 360 µmol/L)   | Dysregulated pyrophosphate       |
|                         | Overproduction vs Underexcretion     | metabolism in aging cartilage    |
| Metabolic Associations  | Metabolic syndrome, obesity, alcohol | Hemochromatosis, primary hyper-  |
|                         | consumption, purines, loop/thiazides | parathyroidism, hypomagnesemia   |
+---------------------------------------------------------------------------------------------------+

Gout: Pathogenesis & Triggers

• Mechanisms of Hyperuricemia: Serum urate saturation threshold is approximately 400 µmol/L (6.8 mg/dL). Hyperuricemia arises from:
  • Underexcretion (90% of cases): Reduced renal tubular clearance of uric acid; exacerbated by renal impairment, volume depletion, and medications—specifically loop and thiazide diuretics, low-dose aspirin, cyclosporine, and pyrazinamide.
  • Overproduction (10% of cases): High purine turnover from myeloproliferative disorders, tumor lysis syndrome, severe psoriasis, hemolytic anemias, or hereditary inborn errors (Lesch-Nyhan syndrome [HPRT deficiency]).
  • Acute Triggers: Heavy alcohol ingestion (beer is rich in purines, and alcohol metabolism generates lactic acid that competes with urate for renal excretion), purine feasts (red meat, seafood, offal), high-fructose corn syrup, dehydration, systemic illness, or sudden fluctuations in serum urate.

Arthrocentesis: The Definitive Diagnostic Gold Standard

Definitive diagnosis of gout or pseudogout requires polarized light microscopy of synovial fluid aspirate. Demonstration of intracellular needle-shaped, negatively birefringent crystals confirms acute gout. (Mnemonic: Y-P-N — Yellow when Parallel = Negative).

• Crucial Exam Pearl: Serum uric acid levels may be normal or even low during an acute gouty attack because systemic inflammatory cytokines promote renal uricosuria; hence, a normal serum uric acid does not exclude acute gout!

Pharmacotherapy of Gout: Acute Flare vs Chronic Urate-Lowering Therapy

1. Management of Acute Gout Flare:
   • First-Line Options (choose based on comorbidities):
     • Oral NSAIDs: High-dose rapidly acting agents (Naproxen 500 mg BID, Indomethacin 50 mg TID) continued for 5 to 7 days. Contraindicated in CKD, active peptic ulcer, or severe heart failure.
     • Oral Colchicine: 1.0 mg followed by 0.5 mg 1 hour later (total 1.5 mg), or 1.2 mg followed by 0.6 mg (total 1.8 mg), according to tablet strength, then 0.5 mg once or twice daily. Must be started within 36 hours of flare onset. Mechanism: Binds beta-tubulin, inhibiting microtubule polymerization and halting neutrophil chemotaxis and NLRP3 inflammasome activation. Adverse effect: dose-dependent diarrhea.
     • Systemic Corticosteroids: Oral Prednisone (30 to 35 mg daily tapered over 5 to 10 days) or intra-articular corticosteroid injection. Drug of choice in patients with chronic kidney disease (CKD) or peptic ulcer disease where NSAIDs and colchicine are unsafe.
2. Chronic Urate-Lowering Therapy (ULT):
   • Indications:
     • Recurrent acute flares (>= 2 flares per year)
     • Presence of subcutaneous tophi (nodular urate crystal deposits with foreign-body giant cell granulomas on ears, olecranon, Achilles tendon)
     • Radiographic evidence of gouty erosions
     • Chronic kidney disease (Stage 2 or greater)
     • Urolithiasis (uric acid nephrolithiasis)
   • First-Line Agent — Allopurinol (Xanthine Oxidase Inhibitor):
     • Started at a low dose (100 mg/day; 50 mg/day in CKD) and titrated upward every 2 to 4 weeks until target serum urate is reached:
     • Target Serum Urate: < 360 µmol/L (< 6.0 mg/dL) for all patients; < 300 µmol/L (< 5.0 mg/dL) if tophaceous gout is present.
     • Genetic Safety Screen: Screen for the HLA-B*5801 allele prior to starting allopurinol in high-risk ancestral groups (Han Chinese, Korean, Thai, African descent) to prevent fatal Severe Cutaneous Adverse Reactions (SCAR: allopurinol hypersensitivity, SJS/TEN).
     • Alternative: Febuxostat (non-purine selective xanthine oxidase inhibitor).
3. CRITICAL PRESCRIBING RULES FOR ULT:
   • Rule 1: NEVER Initiate ULT During an Acute Flare Without Anti-Inflammatory Prophylaxis:
     • Starting ULT can precipitate flares, so prescribe anti-inflammatory prophylaxis. When indicated, ULT may begin during an adequately treated flare; it need not prolong that attack.
     • When starting urate-lowering therapy, concomitant flare prophylaxis must be co-prescribed: Low-dose oral Colchicine (0.5 mg daily) or low-dose oral NSAID (with PPI) for at least 3 to 6 months.
   • Rule 2: NEVER Stop Ongoing ULT During an Acute Flare:
     • If a patient who is already established on allopurinol develops an acute breakthrough flare, DO NOT interrupt or discontinue the allopurinol! Abrupt cessation causes serum urate to rebound sharply, worsening crystal destabilization. Maintain the current allopurinol dose and treat the acute flare with an NSAID, colchicine, or steroid.

---

Septic Arthritis: Acute Orthopedic Emergency

Septic arthritis is an acute bacterial infection of a synovial joint resulting from hematogenous seeding, direct trauma, or percutaneous extension. It represents a limb- and life-threatening orthopedic emergency because lysosomal proteases released by recruited polymorphonuclear neutrophils and chondrocyte collagenases cause irreversible articular chondrolysis and subchondral bone necrosis within 24 to 48 hours.

Clinical Presentation

• Acute, rapid onset of severe, throbbing monoarticular pain, profound swelling, joint warmth, and erythema.
• Hallmark Physical Sign: Severe, near-total restriction of both active and passive range of motion. The patient holds the joint in moderate flexion and strictly resists any attempt at movement.
• Systemic signs: High-grade fever, chills, rigors, and tachycardia (though elderly or immunosuppressed patients may be afebrile).
• Most common site: Knee (> 50% of cases), followed by hip, shoulder, ankle, and wrist.

Microbiology

• Staphylococcus aureus: The most common overall cause across all age groups and risk categories (accounting for > 50-60% of cases), including Methicillin-Resistant S. aureus (MRSA).
• Streptococcus species (Streptococcus pyogenes, Streptococcus pneumoniae, Group B Strep): Second most frequent cause in adults.
• Neisseria gonorrhoeae: Major etiology in sexually active adolescents and young adults (Disseminated Gonococcal Infection [DGI]; classic triad of migratory tenosynovitis, dermatitis with pustular/vesicular skin lesions, and purulent monoarthritis or asymmetric oligoarthritis).
• Gram-Negative Bacilli (E. coli, Pseudomonas aeruginosa): Elderly, immunosuppressed, intravenous drug users, or urinary tract infections.
• Salmonella species: High-frequency pathogen causing septic arthritis and osteomyelitis in patients with Sickle Cell Disease (HbSS) across the Caribbean.

Synovial Fluid Differential Analysis

Obtain urgent synovial fluid and blood cultures before antibiotics when feasible; in sepsis or septic shock, start antibiotics immediately without waiting for aspiration.

Emergency Management Protocol

1. Urgent Diagnostic Arthrocentesis: Collect synovial fluid for cell count, differential, Gram stain, cultures and crystal microscopy before antibiotics when feasible; do not delay antibiotics for aspiration in sepsis/septic shock.
2. Empirical Intravenous Antibiotic Therapy: Administer immediately after arthrocentesis:
   • Standard Adult Empirical: Intravenous Vancomycin (15 to 20 mg/kg IV q12h; covers MRSA and resistant staphylococci) PLUS Intravenous Ceftriaxone (2 g IV daily; covers N. gonorrhoeae and Gram-negative bacilli).
   • Tailor definitively once Gram stain, bacterial cultures, and sensitivities return; total antibiotic duration typically 3 to 4 weeks (minimum 2 weeks IV).
3. Emergency Joint Decompression & Drainage: Antibiotics alone cannot penetrate tense, infected, fibrin-filled joint cavities in concentrations adequate to clear bacteria and proteases. Urgent surgical joint decompression via arthroscopic lavage and irrigation or open arthrotomy must be executed within 24 hours (or serial needle aspiration for accessible joints like the knee).

---

Seronegative Spondyloarthropathies

The Seronegative Spondyloarthropathies (SpA) are a interrelated family of chronic inflammatory arthritides unified by: (1) strong genetic association with HLA-B27, (2) absence of Rheumatoid Factor and Anti-CCP ("seronegative"), (3) predilection for the axial skeleton (sacroiliitis and spondylitis), (4) asymmetrical peripheral oligoarthritis, and (5) enthesitis (inflammation at sites of tendon, ligament, or joint capsule insertion into bone).

Ankylosing Spondylitis (AS)

• Demographics: Typically presents in young men (male-to-female ratio 2-3:1) between ages 15 and 40 years; > 90% are HLA-B27 positive.
• Inflammatory Back Pain Criteria: Insidious onset, duration > 3 months, age of onset < 40 years, morning stiffness lasting > 30 minutes, waking during the second half of the night, and characteristically improves with physical exercise but not with rest.
• Physical Examination:
  • Modified Schober Test: Assesses lumbar flexion restriction. Two points marked 10 cm apart over lumbosacral spine; on full forward flexion, distance should increase by > 5 cm (normal >= 15 cm total). An increase < 5 cm confirms impaired lumbar spine mobility.
  • Chest Expansion: Measured at the 4th intercostal space; restricted expansion (< 2.5 cm) indicates costovertebral joint fusion.
• Imaging:
  • Pelvic Radiograph: Bilateral, symmetrical sacroiliitis (subchondral sclerosis, erosions, pseudo-widening, and complete bony fusion / ankylosis).
  • Spine Radiograph: Squaring of vertebral bodies, ossification of the outer fibers of the annulus fibrosus forming vertical, bridging syndesmophytes, leading to the classic rigid "bamboo spine".
• Extra-Articular Manifestations:
  • Acute Anterior Uveitis (Iritis): Most common extra-articular feature (25-30%); unilateral, painful, red eye with photophobia and blurred vision; requires immediate topical corticosteroids and cycloplegics to prevent posterior synechiae.
  • Cardiovascular: Aortic root dilation, aortic regurgitation, and cardiac conduction blocks.
  • Pulmonary: Apical fibrocavitary disease (predisposes to Aspergillus mycetoma).
• Management: Structured lifelong daily physical therapy and extension exercises; continuous oral NSAIDs (first-line medical therapy); biologic therapy with TNF inhibitors (Infliximab, Adalimumab) or IL-17 inhibitors (Secukinumab) for disease refractory to NSAIDs.

Reactive Arthritis

• Definition: Sterile, post-infectious inflammatory oligoarthritis developing 1 to 4 weeks after an antecedent genitourinary (Chlamydia trachomatis) or gastrointestinal (Campylobacter jejuni, Salmonella, Shigella, Yersinia) infection.
• Classic Clinical Triad: "Can't see, can't pee, can't climb a tree":
  1. Urethritis / Cervicitis: Dysuria, sterile pyuria, urethral discharge.
  2. Conjunctivitis: Bilateral non-purulent conjunctival injection (or anterior uveitis).
  3. Arthritis: Asymmetric, acute oligoarthritis predominantly involving the knees, ankles, and feet; prominent dactylitis ("sausage digits") and severe enthesitis (Achilles tendinitis and plantar fasciitis).
• Cutaneous Hallmarks:
  • Circinate Balanitis: Painless, superficial, serpiginous erosions on the glans penis.
  • Keratoderma Blennorrhagica: Hyperkeratotic, papulosquamous pustular lesions on the palms and soles that closely resemble pustular psoriasis.
• Management: NSAIDs are the mainstay for arthritis; treat documented active Chlamydia genital infection with oral Doxycycline or Azithromycin (including sexual partners).

Psoriatic Arthritis (PsA)

• Develops in up to 30% of patients with cutaneous psoriasis. Symmetrical polyarthritis, asymmetrical oligoarthritis, or exclusive distal interphalangeal (DIP) involvement.
• Clinical Hallmarks: Prominent dactylitis (diffuse, painful sausage-like swelling of an entire digit), nail dystrophy (nail pitting, onycholysis, subungual hyperkeratosis), and radiographic "pencil-in-cup" deformity on hand X-rays (erosion of the proximal phalanx head tapering into a cup-shaped expanded distal phalanx base).

---

Metabolic Bone Diseases

Metabolic bone diseases involve generalized alterations in bone remodeling, mineral homeostasis, and skeletal architectural integrity.

Biochemical Differentiation Matrix

Osteoporosis

• Definition: Progressive systemic skeletal disease characterized by low bone mass, microarchitectural deterioration of bone tissue, and fragility fractures occurring from low-energy trauma (a fall from standing height or less).
• Common Fracture Sites: Vertebral compression fractures (height loss, dorsal kyphosis / "dowager's hump"), femoral neck/intertrochanteric hip fractures (high 1-year excess mortality), and Colles fracture of the distal radius.
• Diagnostic Standard — Dual-Energy X-ray Absorptiometry (DEXA):
  • Scans the lumbar spine and femoral neck/total hip.
  • T-Score: Number of standard deviations (SD) relative to young adult peak reference mean:
    • Normal: T-score >= -1.0 SD
    • Osteopenia: T-score between -1.0 and -2.5 SD
    • Osteoporosis: T-score <= -2.5 SD
    • Severe Osteoporosis: T-score <= -2.5 SD with one or more fragility fractures.
• Pharmacotherapy & CRITICAL BISPHOSPHONATE COUNSELING:
  • First-Line Pharmacological Agents: Oral Bisphosphonates (Alendronate 70 mg weekly, Risedronate 35 mg weekly) or intravenous Zoledronic acid (5 mg yearly). Bisphosphonates inhibit osteoclastic farnesyl pyrophosphate synthase, arresting bone resorption.
  • MANDATORY PATIENT INGESTION INSTRUCTIONS FOR ORAL BISPHOSPHONATES:
    1. Take the tablet first thing in the morning with a full 200-250 mL glass of plain tap water (not mineral water, juice, coffee, or milk).
    2. Take on an entirely empty stomach, at least 30 to 60 minutes before consuming any food, beverages, calcium/vitamin supplements, or other medications.
    3. The patient must remain strictly upright (sitting or standing, never lying down) for at least 30 to 60 minutes after taking the tablet.
    4. Physiological & Safety Rationale: Oral bisphosphonates have poor oral bioavailability (< 1%) and cause severe chemical, erosive esophagitis, esophageal ulceration, and esophageal strictures if retained in the esophagus.
  • Alternative Agents: Denosumab (subcutaneous monoclonal antibody against RANK-ligand; warning: never abruptly stop without transitioning to bisphosphonate due to severe rebound vertebral fractures!), Teriparatide (recombinant PTH analog, anabolic bone formation).

Osteomalacia & Rickets

• Pathophysiology: Inadequate mineralization of newly synthesized organic bone matrix (osteoid) in adults (Osteomalacia), or defective mineralization of growth plate cartilage and osteoid in children prior to epiphyseal fusion (Rickets), most commonly resulting from severe vitamin D deficiency or phosphate wasting.
• Clinical Manifestations: Diffuse, dull, aching bone pain, localized bone tenderness, proximal muscle weakness (causing a characteristic "waddling gait"), and fragility fractures. Children exhibit craniotabes, frontal bossing, rachitic rosary (expansion of costochondral junctions), and bowing deformities of long bones (genu varum).
• Radiographic Hallmark: Generalized osteopenia with Looser Zones (Pseudofractures): narrow, radiolucent bands perpendicular to the cortical bone margins, representing unmineralized osteoid microfractures (characteristically observed on the medial femoral neck, pubic rami, and scapula).
• Adult Nutritional Osteomalacia Treatment: Oral Ergocalciferol (D2) or Cholecalciferol (D3), commonly 50,000 IU weekly for 8 weeks, then maintenance vitamin D and adequate calcium, adjusted to biochemical response. Children with rickets require age-specific vitamin D and calcium for at least 3 months; see Section 12.4.

Paget's Disease of Bone (Osteitis Deformans)

• Pathophysiology: Chronic focal skeletal disorder driven by disorganized, accelerated bone remodeling. Starts with an initial intense phase of excessive osteoclastic bone resorption, followed by erratic, chaotic osteoblastic bone formation. The newly formed bone is expanded, structurally disorganized, hypervascular, and mechanically weak.
• Epidemiology: Typically affects elderly individuals (> 55-60 years), with highest prevalence in individuals of British and European descent.
• Clinical Presentation: Most patients are asymptomatic (diagnosed by incidental isolated elevated ALP). Symptomatic patients present with:
  • Localized bone pain (dull ache, worse at rest and at night; overlying skin feels warm due to bone hypervascularity).
  • Skeletal deformity: Bowing of weight-bearing long bones (saber shins), kyphoscoliosis.
  • Skull Enlargement: Patient reports an increasing hat size or ill-fitting dentures; leontiasis ossea.
  • Sensorineural Hearing Loss: Caused by temporal bone expansion compressing cranial nerve VIII or impinging middle ear ossicles.
• Complications:
  • High-Output Congestive Heart Failure: Hypervascular pagetic bone acts as multiple systemic arteriovenous shunts, markedly increasing cardiac output.
  • Osteosarcoma (Pagetic Sarcoma): Rare (< 1%) but lethal complication; suspected if a patient with stable Paget's develops sudden, severe, localized bone pain and a rapid soft tissue mass.
• Histopathology: Characteristic mosaic or "jigsaw puzzle" pattern of lamellar bone produced by prominent, irregular cement lines separating disorganized osteons.
• Biochemical Hallmark: ISOLATED, MARKED ELEVATION OF SERUM ALKALINE PHOSPHATASE (ALP) with strictly normal serum calcium and normal phosphate.
• Treatment: Intravenous Zoledronic Acid (5 mg single IV infusion) is the first-line treatment of choice, providing rapid and long-lasting normalization of bone turnover; oral Alendronate (40 mg daily for 6 months) is an oral alternative.

---

Worked Clinical Scenarios

Scenario 1: Acute Severe Monoarthritis in an Elderly Diabetic Patient

• Presentation: A 68-year-old man with poorly controlled type 2 diabetes and chronic kidney disease (baseline creatinine 1.8 mg/dL) presents to the emergency department with a 24-hour history of severe, excruciating pain and swelling in his right knee. He woke up with chills, and his temperature is 38.8°C, pulse 110 bpm, and BP 130/80 mmHg. On physical examination, the right knee is markedly swollen, tense, red, and hot. Both active and passive ranges of motion are severely restricted, with the patient screaming in pain upon any attempt at knee flexion.
• Diagnostic Assessment: An acute, hot, swollen monoarticular joint with fever and near-total restriction of active and passive motion is a medical emergency that must be treated as Acute Septic Arthritis until proven otherwise. Although crystal arthropathy (gout or pseudogout) can mimic this presentation, septic arthritis causes irreversible chondrolysis within 24 to 48 hours.
• Management Action: The immediate priority is emergency diagnostic arthrocentesis prior to starting antibiotics. Synovial fluid is aspirated, appearing turbid and purulent. Synovial analysis reveals WBC 118,000/µL with 92% PMNs, low glucose, and Gram-positive cocci in clusters on Gram stain (consistent with Staphylococcus aureus). Polarized microscopy reveals no crystals. Immediate treatment consists of intravenous Vancomycin plus Ceftriaxone, alongside emergency orthopedic consultation for arthroscopic joint lavage and surgical washout within hours. NSAIDs and colchicine cannot treat this joint infection; prioritize antibiotics and drainage, and avoid NSAIDs given his renal impairment.

Scenario 2: Severe Odynophagia in an Osteoporotic Patient

• Presentation: A 74-year-old woman with a DEXA T-score of -3.1 SD at the femoral neck was started on oral Alendronate 70 mg once weekly for osteoporosis 4 weeks ago. She presents to the clinic with severe retrosternal chest pain, painful swallowing (odynophagia), and difficulty swallowing solid foods. When asked about her medication routine, she explains that she takes the alendronate pill with a sip of water right before going to bed at night so she does not forget it.
• Diagnostic Assessment: The patient has developed severe chemical / erosive esophagitis and esophageal ulceration secondary to pill retention, caused by improper bisphosphonate administration. Taking oral bisphosphonates immediately before recumbency with minimal water leads to prolonged mucosal contact, severe tissue irritation, and ulceration.
• Management Action: Oral alendronate must be discontinued immediately. Upper gastrointestinal endoscopy should be performed to evaluate the extent of esophageal mucosal ulceration. The patient should be treated with high-dose Proton Pump Inhibitors. For her underlying osteoporosis, oral bisphosphonates are now contraindicated due to esophageal ulceration; she should be switched to a parenteral antiresorptive agent, such as intravenous Zoledronic acid (5 mg yearly) or subcutaneous Denosumab (60 mg every 6 months).